Galanthamine derivatives for the treatment of Alzheimer's disease

Drugs of the Future

Volumn 21, Issue 6, 1996, Pages 621-635

  Bores, Gina M ^a   Kosley Jr , Raymond W ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; GALANTAMINE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME ACTIVITY; LEARNING; MEMORY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0029920219     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Kewitz, H., Wilcock, G., Davis, B. Galanthamine in Alzheimer's disease. In: Alzheimer Disease: Therapeutic Strategies. Giacobini E., Becker, R. (Eds.). Birkäuser: Boston 1994, 140-4.
2. Thomsen, T., Bickel, U., Fischer, J.P., Kewitz, H. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1990, 1: 46-51.
3. Bartus, R.T., Dean, R.L., Beer, B., Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217: 408-17.
4. Coyle, J.T. Price, D.L., Delong, M.R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219: 1184-90.
5. Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T., Delong, M.R. Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981, 10: 122.
6. Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., DeLong, M.R. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215: 1237-9.
7. Becker, R.E., Giacobini, E. Mechanisms of ChE inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Dev Res 1988, 12: 163-95.
8. Pomponi, M., Giacobini, E., Brufani, M. Present state and future development of the therapy of Alzheimer disease. Aging 1990, 2: 125-53.
9. Davis, K.L., Thal, L.J., Gamzu, E.R. et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New Engl J Med 1992, 327: 1253-9.
10. Proskurnina, N.F., Areshknina, L.Y. Alkaloids of Galanthus woronovi. Zh Obshch Khim 1947, 17: 1216.
11. Proskurnina, N.F., Yakovleva, A.P. Alkaloids of Galanthus woronovi. II. Isolation of a new alkaloid. Zh Obshch Khim 1952, 22: 1899.
12. Uyeo, S., Kobayashi, S. Lycoris alkaloids. XXIV. Isolation and characterization of lycoremine. Pharm Bull 1953, 1: 139.
13. Kobayashi, S., Shingu, T., Uyeo, S. Structure of galanthamine and lycoramine. Chem Ind 1956, 177.
14. Irwin, R.L., Smith, H.J. The activity of galanthamine and related compounds on muscle. Arch Int Pharmacodyn 1960, 127: 314.
15. Schuh, F.T. Molecular mechanism of action of galanthamine, a curare antagonist. Anaesthetist 1976, 25: 444-8.
16. Sweeney, J.E., Puttfarcken, P.S., Coyle, J.T. Galanthamine, an acetylChE inhibitor: A time course of the effects on performance and neurochemical parameters in mice. Pharmacol Biochem Behav 1989, 34: 129-37.
17. Thomsen, T., Kewitz, H. Comparison of acetyl- and butyrylChE inhibition as due to reversible enzyme inhibitors. Clin Biochem 1989, 22: 411.
18. Thomsen, T., Zendeh, B., Fischer, J.P., Kewitz, H. In vitro effects of various ChE inhibitors on acetyl- and butyrylChE of healthy volunteers. Biochem Pharmacol 1991, 41: 139-41.
19. Pestel, M. A novel medication for the treatment of myasthenia gravis and muscular dystrophy: Nivalin®. Nouv Presse Med 1961, 69: 182.
20. Bickel, U., Thomsen, T., Weber, W. et al. Pharmacokinetics of galanthamine in humans and corresponding ChE inhibition. Clin Pharmacol Ther 1991, 50: 420-8.
21. Mihailova, D., Yamboliev, I., Zhivkova, Z., Tencheva, J., Jovovich, V. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 1989, 39: 50-8.
22. Rainer, M., Mark, T., Haushofer, A. Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer's type. In: Pharmacological Interventions on Central Cholinergic Mechanisms in Senile Dementia. Kewitz, H., Bickel, U. (Eds.). W Zuckschwerdt Verlag: München 1989, 233-7.
23. Uyeo, S., Shirai, H., Koshiro, A., Yashiro, T., Kagei, K. Galanthamine chemistry, VII. Synthesis of analogues of galanthamine. Chem Pharm Bull 1966, 14: 1033-9.
24. Sticht Biomedical Research. New 6-demethylgalanthamine derivatives useful as antiChE agents. NL 8800350-A.
25. Han, S.Y., Sweeney, J.E., Bachman, E.S. et al. Chemical and pharmacological characterization of galanthamine, an acetylChE inhibitor, and its derivatives. A potential application in Alzheimer's disease. Eur J Med Chem 1992, 27: 673-87.
26. Kosley, R.W. Jr., Rauckman, B.S., Wolf, V., Wong, G. A convenient, high yield procedure for the O-demethylation of galanthamine. J Org Chem, in press.
27. Shieh, W-C., Carlson, J. Asymmetric transformations of either enantiomer of narwedine via total spontaneous resolution process, a concise solution to the synthesis of galanthamine. J Org Chem 1994, 59: 5463-5.
28. Barton, D.H.R., Kirby, G. Phenol oxidation and biosynthesis. Part V. The synthesis of galanthamine. J Chem Soc 1962, 806.
29. Kametani, T., Shishido, K., Hayashi, E. et al. Studies on the synthesis of heterocyclic compounds. CCCXCVI. An alternative total synthesis of (±)-galanthamine. J Org Chem 1971, 36: 1295.
30. Shimizu, K., Tomioka, K., Yamada, S., Koga, K. A biogenetic-type asymmetric synthesis of optically active amaryllidaceae alkaloids: (+)- and (-)-galanthamine from L-tyrosine. Heterocycles 1977, 8: 277.
31. Szewczyk, J., Wilson, J., Lewin, A., Carroll, F. Facile synthesis of (±), (+)- and (-) galanthamine. J Heterocycle Chem 1988, 25: 1809.
32. Vlahov, R., Krikorian, D., Spassov, G. et al. Synthesis of galanthamine and related alkaloids - New approaches. I. Tetrahedron 1989, 45: 3329.
33. Holton, R., Sibi, M., Murphy, W. Palladium-mediatedbiomimetic synthesis of narwedine. J Amer Chem Soc 1988, 110: 314.
34. Czollner, L., Froehlich, J., Jordis, U., Kueenburg, B. Production of new or known galanthamine compounds from benzaldehyde and phenethylamine derivatives. WO 383279/50.
35. Bores, G., Huger, F., Petko, W. et al. Evaluation of P11012 and P11149 for the treatment of Alzheimer's disease. 3rd Int Springfield Symp Adv Alzheimer Ther 1994, Abst P11.
36. Bores, G.M., Huger, F.P., Petko, W. et al. Pharmacological evaluation of novel Alzheimer disease therapeutics: AcetylChE inhibitors related to galanthamine. JPET 1996, 277: 728-38.
37. Davis, L., Fink, D., Rauckman, B. et al. Galanthamine derivatives as agents for the treatment of Alzheimer's disease. 209th ACS Natl Meet 1995, Abst MEDI 91.
38. Ellman, G.L., Courtney, K.D., Andres, V. Jr., Featherstone, R.M. A new and rapid colorimetric determination of acetylChE activity. Biochem Pharmacol 1961, 7: 88-95.
39. Thomsen, T., Kewitz, H. Selective inhibition of human acetylChE by galanthamine in vitro and in vivo. Life Sci 1990, 46: 1553-8.
40. Thomsen, T., Kewitz, H., Pleul, O. Estimation of ChE activity (EC3.1.1.7;3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring in vivo effects of reversible inhibitors. J Clin Chem Clin Biochem 1988, 26: 469-75.
41. Zakirov, U., Umarova, S. Comparative study of some pharmacological properties of epigalanthamine and galanthamine. Farmakol Alkaloidov Serdech Glikozidov 1971, 96-100.
42. Bores, G.M., Huger, F.P., Usu, R.S. et al. HP 290: A potent, orally active ChE inhibitor for the treatment of Alzheimer's disease. 21st Soc Neurosci Meet 1991, 17: Abst 274.3.
43. Bickel, U., Thomsen, T., Fischer, J.P., Weber, W., Kewitz, H. Galanthamine: Pharmacokinetics, tissue distribution and ChE inhibition in brain of mice. Neuropharmacology 1991, 30: 447-54.
44. Wilson, I.B., Hatch, M.A., Ginsberg, S. Carbamylation of acetylChE. J Biol Chem 1960, 235: 2312.
45. Dressel, T.D., Goodale, R.L., Borner, J.W., Etani, S.E. A study of the ChEs of the canine pancreatic sphincters and the relationship between reduced butyrylChE activity and pancreatic ductal hypertension. Ann Surg 1980, 192: 614-8.
46. Gupta, R.C., Dettbarn, W.D. Iso-OMPA-induced potentiation of soman toxicity in rat. Arch Toxicol 1987, 61: 58-62.
47. Koelle, W.A., Koelle, G.B., Smyrl, E.G. Effects of persistent selective suppression of ganglionic butyrylChE on steady state and regenerating levels of acetylChE: Implications regarding function of butyrylChE and regulation of protein synthesis. Proc Natl Acad Sci USA 1976, 73: 2936-8.
48. Prody, C.A., Dreyfus, P., Zamir, R., Zakut, H., Soreq, H. De novo amplification within a 'silent' human ChE gene in a family subjected to prolonged exposure to organophosphorous insecticides. Proc Natl Acad Sci USA 1989, 86: 690-4.
49. Gordon, C.J. Thermoregulation in laboratory mammals and humans exposed to antiChE agents. Neurotoxicol Teratol 1994, 16: 427-53.
50. Porsolt, R.D., Roux, S., Wettstein, J.G. Research overview of animal models of dementia. Drug Dev Res 1995, 35: 214-29.
51. Chopin, P., Briley, M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 1992, 106: 26-30.
52. Sweeney, J.E., Bachman, E.S., Coyle, J.T. Effects of different doses of galanthamine, a long-acting acetylChE inhibitor, on memory in mice. Psychopharmacology 1990, 102: 191-200.
53. 2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 1996, 124: 347-54.
54. Rush, D.K., Streit, K. Memory modulation with peripherally acting cholinergic drugs. Psychopharmacology 1992, 106: 375-82.
55. Fishkin, R.J., Ince, E.S., Carlezon, W.A. Jr., Dunn, R.W. D-Cycloserine attenuates scopolamine-induced learning and memory deficits in rats. Behav Neural Biol 1993, 59: 150-7.
56. Waite, J.J., Thal, L.J. The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis. Neurosci Res 1995, 21: 251-9.
57. Mihailova, D., Yamboliev, I. Pharmacokinetics of galanthamine hydrobromide (Nivalin®) following single intravenous and oral administration in rats. Pharmacology 1986, 32: 301-6.